First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter

OBJECTIVES The aim of this study was to explore the safety and efficacy of a dedicated drug-eluting stent for the treatment of coronary lesions with very small reference vessel diameter (RVD). BACKGROUND Smaller RVD is associated with increased risk for restenosis and target lesion failure (TLF) after stent implantation. METHODS This was a prospective, single-arm, multicenter trial of the Resolute Onyx 2.0-mm zotarolimus- eluting stent. The primary endpoint was 12-month TLF, which was compared with a pre-specified performance goal. Subjects with stable or unstable angina or ischemia, target lesions <= 27 mm in length, and RVD >= 2.0 and <2.25 mm were eligible for enrollment. A subset of subjects underwent follow-up angiography at 13 months post-procedure. RESULTS A total of 101 subjects with 104 lesions were enrolled. The mean age was 67.3 +/- 9.6 years, 47% of subjects had diabetes, the mean lesion length was 12.6 +/- 6.3 mm, and the mean RVD was 1.91 +/- 0.26 mm. The rate of TLF at 12 months was 5.0%, fulfilling the pre- specified performance goal of 19% ( p < 0.001). The rates of target lesion revascularization and target vessel myocardial infarction were 2.0% and 3.0%, respectively. There were no episodes of stent thrombosis. In-stent late lumen loss was 0.26 +/- 0.48 mm, and the rate of binary restenosis was 12.0%. CONCLUSIONS In this first report of a drug-eluting stent with a dedicated size to treat lesions with RVD < 2.25 mm, the Resolute Onyx 2.0-mm zotarolimus- eluting stent was associated with a low rate of TLF and late lumen loss, without a signal for stent thrombosis. This novel-sized drug-eluting stent appears to be a feasible option for the treatment of coronary lesions in extremely small vessels. (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.